<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316953</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01824</org_study_id>
    <secondary_id>ADVL0516</secondary_id>
    <secondary_id>U10CA97452</secondary_id>
    <secondary_id>CDR0000467233</secondary_id>
    <nct_id>NCT00316953</nct_id>
  </id_info>
  <brief_title>Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate</brief_title>
  <official_title>A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (BMS Trial CA180038)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of dasatinib in treating young&#xD;
      patients with recurrent or refractory solid tumors or Philadelphia chromosome-positive acute&#xD;
      lymphoblastic leukemia or chronic myelogenous leukemia that did not respond to imatinib&#xD;
      mesylate. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the toxicities and estimate the maximum tolerated dose or the recommended phase&#xD;
      2 dose of dasatinib in pediatric patients with refractory solid tumors.&#xD;
&#xD;
      II. Determine the toxicities of dasatinib in pediatric patients with imatinib&#xD;
      mesylate-resistant Philadelphia chromosome-positive (Ph+) leukemia.&#xD;
&#xD;
      III. Characterize the pharmacokinetics of dasatinib in pediatric patients with refractory&#xD;
      solid tumors or imatinib-resistant Ph+ leukemia.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Preliminarily define the antitumor activity of dasatinib in pediatric patients with&#xD;
      refractory solid tumors within the confines of a phase I study.&#xD;
&#xD;
      II. Obtain pilot data on the activity of dasatinib administered in pediatric patients with&#xD;
      Ph+ leukemia.&#xD;
&#xD;
      III. Assess the biologic activity of dasatinib on tumor cells when available. IV. Determine&#xD;
      the phosphotyrosine state of SRC and ABL substrates and correlate this with dasatinib dosage&#xD;
      and antitumor activity (pharmacodynamics study).&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study. Patients are stratified according to&#xD;
      disease (solid tumors vs leukemia).&#xD;
&#xD;
      Stratum 1 (solid tumors): Patients receive oral dasatinib twice daily on days 1-28. Treatment&#xD;
      repeats every 28 days for up to 24 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of dasatinib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which ≥ 2 of 6&#xD;
      patients experience dose-limiting toxicity (DLT).&#xD;
&#xD;
      Stratum 2 (leukemia): Patients receive dasatinib as in stratum 1. Cohorts of 3-12 patients&#xD;
      receive escalating or de-escalating doses of dasatinib. The MTD is defined as the dose&#xD;
      preceding that at which 7 of 12 patients experience DLT.&#xD;
&#xD;
      After completing study treatment, patients are followed for 1 month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose defined as the maximum dose at which fewer than 1/3 patients experience dose-limiting toxicities (DLT) graded according to CTCAE</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>Interval from enrollment to disease progression, death, occurrence of a second malignant neoplasm or last patient contact, assessed up to 1 month</time_frame>
    <description>Will be estimated separately for patients on the solid tumor and on the refractory Ph+ leukemia strata with the Kaplan Meier method.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Chronic Myelogenous Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Meningeal Chronic Myelogenous Leukemia</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Stratum 1 (solid tumors)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 2 (leukemia)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dasatinib as in stratum 1. Cohorts of 3-12 patients receive escalating or de-escalating doses of dasatinib. The MTD is defined as the dose preceding that at which 7 of 12 patients experience DLT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Stratum 1 (solid tumors)</arm_group_label>
    <arm_group_label>Stratum 2 (leukemia)</arm_group_label>
    <other_name>BMS-354825</other_name>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Stratum 1 (solid tumors)</arm_group_label>
    <arm_group_label>Stratum 2 (leukemia)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Stratum 1 (solid tumors)</arm_group_label>
    <arm_group_label>Stratum 2 (leukemia)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Malignant extracranial solid tumor&#xD;
&#xD;
                    -  Recurrent or refractory disease&#xD;
&#xD;
                    -  Known bone marrow metastases* allowed&#xD;
&#xD;
               -  Imatinib mesylate-resistant Philadelphia chromosome-positive (Ph+) acute&#xD;
                  lymphoblastic leukemia (ALL), defined as M3 bone marrow in a patient who&#xD;
                  previously received imatinib mesylate-containing treatment regimen&#xD;
&#xD;
               -  Imatinib mesylate-resistant Ph+ chronic myelogenous leukemia (CML), as defined by&#xD;
                  any of the following:&#xD;
&#xD;
                    -  Increasing WBC or platelet count while on imatinib mesylate therapy&#xD;
&#xD;
                    -  Lack of any cytogenetic response after an adequate duration of imatinib&#xD;
                       mesylate therapy, as defined by 1 of the following:&#xD;
&#xD;
                         -  Failed to achieve a complete hematologic response after completion of 3&#xD;
                            months of imatinib mesylate treatment&#xD;
&#xD;
                         -  Failed to achieve a partial or complete cytogenetic response (i.e., ≤&#xD;
                            35% Ph+ cells) after 6 months of imatinib mesylate treatment&#xD;
&#xD;
                    -  Appearance of accelerated or blastic feature while on imatinib mesylate&#xD;
                       therapy&#xD;
&#xD;
                    -  Reappearance of Ph+ clones after an initial complete cytogenetic response to&#xD;
                       imatinib mesylate&#xD;
&#xD;
                    -  More than 30% increase in Ph+ cells in peripheral blood or bone marrow&#xD;
                       cytogenetics while on imatinib mesylate therapy&#xD;
&#xD;
                    -  Imatinib mesylate intolerance, as defined by development of adverse effects&#xD;
                       requiring discontinuation of imatinib mesylate therapy&#xD;
&#xD;
          -  Measurable disease (for patients with CML or ALL)&#xD;
&#xD;
               -  Determined by hematologic, cytogenetic, and molecular studies for CML&#xD;
&#xD;
               -  Determined by bone marrow blast percentage for ALL&#xD;
&#xD;
          -  Measurable or evaluable disease (for patients with solid tumors)&#xD;
&#xD;
          -  No known curative therapy or survival-prolonging therapy with an acceptable quality of&#xD;
             life&#xD;
&#xD;
          -  No CNS solid tumors&#xD;
&#xD;
               -  CNS-positive leukemia allowed&#xD;
&#xD;
          -  Karnofsky performance status (PS) ≥ 50% (for patients &gt; 10 years of age)&#xD;
&#xD;
          -  Lansky PS ≥ 50% (for patients ≤ 10 years of age)&#xD;
&#xD;
          -  No evidence of graft-vs-host disease&#xD;
&#xD;
          -  Solid tumors:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,000/mm^3 (750/mm^3 if bone marrow infiltration)&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm^3 (transfusion independent) (50,000/mm^3 if bone&#xD;
                  marrow infiltration)&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dL (red blood cell [RBC] transfusions allowed)&#xD;
&#xD;
          -  ALL/CML:&#xD;
&#xD;
               -  Platelet count ≥ 20,000/mm^3 (platelet transfusions allowed)&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR&#xD;
             creatinine based on age, as follows:&#xD;
&#xD;
               -  No greater than 0.6 mg/dL (1-23 months of age)&#xD;
&#xD;
               -  No greater than 0.8 mg/dL (2- 5 years of age)&#xD;
&#xD;
               -  No greater than 1.0 mg/dL (6-9 years of age)&#xD;
&#xD;
               -  No greater than 1.2 mg/dL (10-12 years of age)&#xD;
&#xD;
               -  No greater than 1.4 mg/dL (13 years of age and over [female])&#xD;
&#xD;
               -  No greater than 1.5 mg/dL (13-15 years of age [male])&#xD;
&#xD;
               -  No greater than 1.7 mg/dL (16 years of age and over [male])&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT ≤ 110 U/L&#xD;
&#xD;
          -  Albumin ≥ 2 g/dL&#xD;
&#xD;
          -  Normal 12-lead EKG with corrected QTc &lt; 450 msec AND meets 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Shortening fraction normal&#xD;
&#xD;
               -  Ejection fraction normal&#xD;
&#xD;
          -  No evidence of dyspnea at rest&#xD;
&#xD;
          -  No exercise intolerance&#xD;
&#xD;
          -  Pulse oximetry &gt; 94% if there is a clinical indication for determination&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No swallowing dysfunction that would prevent taking an oral or liquid medication&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior chemotherapy, immunotherapy, or radiotherapy&#xD;
&#xD;
          -  No myelosuppressive chemotherapy within the past 3 weeks (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  At least 7 days since prior growth factors&#xD;
&#xD;
          -  At least 14 days since prior pegfilgrastim&#xD;
&#xD;
          -  At least 7 days since prior biologic agents&#xD;
&#xD;
          -  At least 2 weeks since prior local small-port palliative radiotherapy&#xD;
&#xD;
          -  At least 3 months since prior total-body irradiation, craniospinal radiation, or&#xD;
             radiation to ≥ 50% of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow radiation&#xD;
&#xD;
          -  At least 3 months since prior stem cell transplantation&#xD;
&#xD;
          -  Hydroxyurea cytoreduction for Ph+ leukemia allowed provided it is discontinued 24&#xD;
             hours before first dose of dasatinib&#xD;
&#xD;
          -  Prior intrathecal (IT) therapy allowed (for patients with CNS-positive leukemia)&#xD;
&#xD;
          -  Concurrent IT therapy comprising hydrocortisone, cytarabine, methotrexate, or&#xD;
             cytarabine (liposomal) allowed (for patients with CNS-positive leukemia)&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer agents, including chemotherapy, radiotherapy,&#xD;
             immunotherapy, or biologic therapy&#xD;
&#xD;
          -  No concurrent enzyme-inducing anticonvulsants, including any of the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Felbamate&#xD;
&#xD;
               -  Primdone&#xD;
&#xD;
               -  Oxcarbazepine&#xD;
&#xD;
          -  No concurrent antithrombotic or antiplatelet agents, including any of the following:&#xD;
&#xD;
               -  Warfarin&#xD;
&#xD;
               -  Heparin&#xD;
&#xD;
               -  Low-molecular weight heparin&#xD;
&#xD;
               -  Aspirin&#xD;
&#xD;
               -  Ibuprofen&#xD;
&#xD;
               -  Other nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
          -  No concurrent CYP3A4 inhibitors, including itraconazole, ketoconazole, and&#xD;
             voriconazole&#xD;
&#xD;
          -  No concurrent highly active antiretroviral treatment for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Aplenc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>April 19, 2006</study_first_submitted>
  <study_first_submitted_qc>April 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2006</study_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

